Trending Content - Off Topic Forum
| +73 | Uchicago is paradise | 14 | 3d |
| +61 | BofA VP killed in random NYC stabbing | 36 | 2d |
| +46 | What Bank Will Make Women Instantly Fall In Love With Me? | 14 | 2d |
| +39 | Who Killed Wall Street | 7 | 3h |
| +14 | Western Investment Bankers Deserve No-Minimum-Wage Nannies, and I Want Mine NOW | 2 | 3h |
| +12 | At what salary can you start calling it “fi-NANCE” | 3 | 1d |
| +11 | Lindsay Clansey | 6 | 7h |
| +9 | Wrote a rap song on finance | 1 | 10h |
| +7 | Who is making these posts on WSO Linkedin ? | 5 | 3d |
| +1 | Someone just coined "the view" | 3 | 4d |
Career Resources
Well, they aren't expected to generate positive EPS in 2012, so valuing them on a multiple basis isn't possible.
They missed on earnings and their arthritis drug isn't expected to generate top line growth til late 2012.
I don't know much more than that after a quick run through on them. Sounds like a 2013 story if anything, though.
don't know about that shit. if you want to play bio pick up DNDN, AMRN or AEZS, especially at theses levels.
it's been an adjustment in risk for all of the bio stocks since DNDN; worry is about the level of reimbursement from Medicaire for the high-priced drugs. Medicaire doesn't look to price / affordability only efficacy when it decides reimbursement. Obviously, that law can change if Medicaire is restructured.
disclosure: I'm obviously in all of them
Tempore sit assumenda cupiditate laboriosam iusto dicta doloribus. Delectus aut non sed qui a et ea. Earum aliquid eligendi porro est quia. Deleniti odio distinctio autem nihil est.
Voluptatibus et eveniet dolorum nemo. Voluptatibus esse eos voluptatem fuga recusandae. Sequi aut ipsam qui fugit at. Ea quis sit repellat rerum enim.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...